0001209191-19-004547.txt : 20190118
0001209191-19-004547.hdr.sgml : 20190118
20190118161303
ACCESSION NUMBER: 0001209191-19-004547
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180323
FILED AS OF DATE: 20190118
DATE AS OF CHANGE: 20190118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Flynn Daniel Lee
CENTRAL INDEX KEY: 0001713712
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 19533385
MAIL ADDRESS:
STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC
STREET 2: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-23
0
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001713712
Flynn Daniel Lee
C/O DECIPHERA PHARMACEUTICALS, INC.
500 TOTTEN POND ROAD
WALTHAM
MA
02451
0
1
0
0
Chief Scientific Officer
Common Stock
2018-03-23
5
G
0
E
91779
0.00
A
91779
I
By Daniel L. Flynn Irrevocable Trust
Common Stock
2018-03-23
5
G
0
E
91779
0.00
D
55270
I
By Biochenomix, LLC
Common Stock
2019-01-16
4
M
0
152629
1.89
A
152629
D
Common Stock
2019-01-16
4
S
0
152629
26.00
D
0
D
Stock Option (Right to Buy)
1.89
2019-01-16
4
M
0
152629
0.00
D
2025-12-17
Common Stock
152629
472678
D
This transaction involved a transfer of shares to the Daniel L. Flynn Irrevocable Trust from Biochenomix, LLC. The Reporting Person's daughter is trustee of the trust and the Reporting Person's spouse is the sole lifetime beneficiary of the trust. The Reporting Person disclaims Section 16 beneficial ownership over all such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that the Reporting Person has beneficial ownership of such shares for Section 16 or for any other purposes.
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.
/s/ Jeffrey M. Held, Attorney-in-Fact
2019-01-18